title: Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands.
abstract: BACKGROUND
  Recent studies suggested an improved overall survival (OS) for BRCA2- versus BRCA1-associated epithelial ovarian cancer (EOC), whereas the impact of chemotherapy is not yet clear. In a nationwide cohort, we examined the results of primary treatment, progression-free survival (PFS), treatment-free interval (TFI), and OS of BRCA1 versus BRCA2 EOC patients.
  
  
  METHODS
  Two hundred and forty-five BRCA1- and 99 BRCA2-associated EOC patients were identified through all Dutch university hospitals. Analyses were carried out with the Pearson's Chi-square test, Kaplan-Meier, and Cox regression methods.
  
  
  RESULTS
  BRCA1 patients were younger at EOC diagnosis than BRCA2 patients (51 versus 55 years; P < 0.001), without differences regarding histology, tumor grade, and International Federation of Gynecology and Obstetrics (FIGO) stage. Complete response rates after primary treatment, including chemotherapy, did not differ between BRCA1 (86%) and BRCA2 patients (90%). BRCA1 versus BRCA2 patients had a shorter PFS (median 2.2 versus 3.9 years, respectively; P = 0.006), TFI (median 1.7 versus 2.8 years; P = 0.009), and OS (median 6.0 versus 9.7 years; P = 0.04). Differences could not be explained by age at diagnosis, FIGO stage or type of treatment.
  
  
  CONCLUSIONS
  PFS and OS were substantially longer in BRCA2- than in BRCA1-associated EOC patients. While response rates after primary treatment were similarly high in both groups, TFI, as surrogate for chemosensitivity, was significantly longer in BRCA2 patients.
authors.affiliation: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Erasmus University Medical Center, Rotterdam, The Netherlands.
authors.forename: P M L H
authors.initials: PM
authors.lastname: Vencken
authors.forename: W
authors.initials: W
authors.lastname: Reitsma
authors.forename: M
authors.initials: M
authors.lastname: Kriege
authors.forename: M J E
authors.initials: MJ
authors.lastname: Mourits
authors.forename: G H
authors.initials: GH
authors.lastname: de Bock
authors.forename: J A
authors.initials: JA
authors.lastname: de Hullu
authors.forename: A M
authors.initials: AM
authors.lastname: van Altena
authors.forename: K N
authors.initials: KN
authors.lastname: Gaarenstroom
authors.forename: H F A
authors.initials: HF
authors.lastname: Vasen
authors.forename: M A
authors.initials: MA
authors.lastname: Adank
authors.forename: M K
authors.initials: MK
authors.lastname: Schmidt
authors.forename: M
authors.initials: M
authors.lastname: van Beurden
authors.forename: R P
authors.initials: RP
authors.lastname: Zweemer
authors.forename: F
authors.initials: F
authors.lastname: Rijcken
authors.forename: B F M
authors.initials: BF
authors.lastname: Slangen
authors.forename: C W
authors.initials: CW
authors.lastname: Burger
authors.forename: C
authors.initials: C
authors.lastname: Seynaeve
mesh_terms: D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D019313:BRCA1 Protein / Q000235:genetics*; D024682:BRCA2 Protein / Q000235:genetics*; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality* / Q000601:surgery; D009426:Netherlands; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000401:mortality* / Q000601:surgery; D017239:Paclitaxel / Q000627:therapeutic use; D017671:Platinum Compounds / Q000627:therapeutic use; D013534:Survival; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D019313:BRCA1 Protein; C492913:BRCA1 protein, human; D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D017671:Platinum Compounds; D017239:Paclitaxel
keywords: BRCA1; BRCA2; chemotherapy; ovarian cancer; response; survival